Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PA-MSHA promotes antitumor immunity in STK11 mutant NSCLC through activating the STING pathway of immune cells.

International immunopharmacology - 15 Jul 2026

Yin Guofang, He Fang, Guo Qiusha, Jiang Qilan, Fan Shiming, Liu Yue, Fan Xiaoqing, Liang Yuling, Luo Dan, Jin Kaiyu, Wang Zhiguo, Fan Xianming

Abstract excerpt

BACKGROUND: Serine/threonine kinase 11 (STK11) mutant non-small cell lung cancer (NSCLC) exhibits primary resistance to immunotherapy due to a "cold" tumor immune microenvironment (TIME). Therefore, patients with STK11 mutation benefit little from immunotherapy, highlighting the need to explore novel therapeutic strategies for this population. METHODS: The impact of Pseudomonas aeruginosa...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Jurkat Cells

Share to Lung Neoplasms

Share to Membrane Proteins

Share to Protein Serine-Threonine Kinases

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 42070312
DOI: 10.1016/j.intimp.2026.116763

Genes

STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PA-MSHA promotes antitumor immunity in STK11 mutant NSCLC through activating the STING pathway of immune cells.PMID 42070312Read ↗

STK11 mutation affects the killing effect of NK cells to promote the progression of lung adenocarcinoma.Semantic proximity Read ↗

Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy.Semantic proximity Read ↗

The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.Semantic proximity Read ↗

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.Semantic proximity Read ↗

STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.Semantic proximity Read ↗

PA-MSHA inhibits proliferation and induces apoptosis in human non-small cell lung cancer cell lines with different genotypes.Semantic proximity Read ↗

Pharmacological rescue of tumor intrinsic STING expression and immune response in LKB1-mutant lung cancer via the IAP-JAK regulatory axisSemantic proximity Read ↗

Low STING expression in a transplantable Kras <sup>G12D</sup> /P53 <sup>ko</sup> lung cancer model contributes to SiglecF <sup>+</sup> neutrophil and CD103 <sup>+</sup> Treg accumulation in tumorsSemantic proximity Read ↗

Targeted Delivery of STING agonist via Albumin Nanoreactor Boosts Immunotherapeutic Efficacy against Aggressive CancersSemantic proximity Read ↗

Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments.Semantic proximity Read ↗

A STING operation to expose KRAS and STK11 co-mutated lung cancers.Semantic proximity Read ↗

A molecularly engineered lectin destroys EGFR and inhibits the growth of non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.